Cyclerion Therapeutics (CYCN) to Release Quarterly Earnings on Tuesday

Posted by Andrew Walz on Feb 24th, 2026

Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) will likely be issuing its results before the market opens on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.

Cyclerion Therapeutics Stock Down 1.5%

CYCN stock opened at $1.32 on Tuesday. The company has a 50-day simple moving average of $1.39 and a 200 day simple moving average of $1.86. The company has a market capitalization of $5.19 million, a P/E ratio of -1.76 and a beta of 0.98. Cyclerion Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $3.79.

Hedge Funds Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 75.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

View Our Latest Research Report on Cyclerion Therapeutics

About Cyclerion Therapeutics

(Get Free Report)

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.